Molecular Cancer Genetics & Translational Research Lab, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India.
Molecular Toxicology & Cytogenetics Lab, Section of Genetics, Department of Zoology, Aligarh Muslim University, Aligarh-202002, Uttar Pradesh, India.
Curr Pharm Des. 2020;26(4):455-465. doi: 10.2174/1381612826666200122122804.
The resistance of cancer cells to different therapies is one of the major stumbling blocks for successful cancer treatment. Various natural and pharmaceuticals drugs are unable to control drug-resistance cancer cell's growth. Also, chemotherapy and radiotherapy have several side effects and cannot apply to the patient in excess. In this context, chemosensitization to the therapy-resistant cells by non-toxic phytochemicals could be an excellent alternative to combat therapy-resistant cancers.
To review the currently available literature on chemosensitization of therapy resistance cancers by Lupeol for clinically approved drugs through targeting different cell signaling pathways.
We reviewed relevant published articles in PubMed and other search engines from 1999 to 2019 to write this manuscript. The key words used for the search were "Lupeol and Cancer", "Lupeol and Chemosensitization", "Lupeol and Cell Signaling Pathways", "Cancer Stem Cells and Lupeol" etc. The published results on the chemosensitization of Lupeol were compared and discussed.
Lupeol chemosensitizes drug-resistant cancer cells for clinically approved drugs. Lupeol alone or in combination with approved drugs inhibits inflammation in different cancer cells through modulation of expression of IL-6, TNF-α, and IFN-γ. Lupeol, through altering the expression levels of BCL-2, BAX, Survivin, FAS, Caspases, and PI3K-AKT-mTOR signaling pathway, significantly induce cell deaths among therapy-resistant cells. Lupeol also modulates the molecules involved in cell cycle regulation such as Cyclins, CDKs, P53, P21, and PCNA in different cancer types.
Lupeol chemosensitizes the therapy-resistant cancer cells for the treatment of various clinically approved drugs via modulating different signaling pathways responsible for chemoresistance cancer. Thus, Lupeol might be used as an adjuvant molecule along with clinically approved drugs to reduce the toxicity and increase the effectiveness.
癌细胞对不同疗法的耐药性是癌症治疗成功的主要障碍之一。各种天然和药物药物都无法控制耐药癌细胞的生长。此外，化疗和放疗有许多副作用，不能过量应用于患者。在这种情况下，用无毒植物化学物质使耐药细胞对化疗增敏可能是对抗耐药性癌症的极好替代方法。
综述目前关于羽扇豆醇通过靶向不同细胞信号通路使治疗耐药性癌症对临床批准药物增敏的文献，以用于临床。
我们检索了 1999 年至 2019 年在 PubMed 和其他搜索引擎上发表的相关文章，以撰写本文。用于搜索的关键词是“羽扇豆醇和癌症”、“羽扇豆醇和化疗增敏”、“羽扇豆醇和细胞信号通路”、“癌症干细胞和羽扇豆醇”等。比较和讨论了羽扇豆醇增敏作用的已发表结果。
羽扇豆醇使耐药癌细胞对临床批准药物增敏。羽扇醇单独或与批准药物联合使用，通过调节 IL-6、TNF-α 和 IFN-γ 的表达来抑制不同癌细胞中的炎症。羽扇豆醇通过改变 BCL-2、BAX、Survivin、FAS、Caspases 和 PI3K-AKT-mTOR 信号通路的表达水平，显著诱导耐药细胞死亡。羽扇豆醇还调节不同癌症类型中细胞周期调节分子，如细胞周期蛋白、CDKs、P53、P21 和 PCNA。
羽扇豆醇通过调节与化疗耐药性相关的不同信号通路，使耐药性癌症细胞对各种临床批准药物增敏。因此，羽扇醇可以作为一种辅助分子与临床批准药物联合使用，以降低毒性并提高疗效。
